Amedisys FY2024 EPS Estimate Lowered by Leerink Partnrs

Amedisys, Inc. (NASDAQ:AMED) – Stock analysts at Leerink Partnrs cut their FY2024 earnings per share (EPS) estimates for shares of Amedisys in a report released on Wednesday, January 29th. Leerink Partnrs analyst W. Mayo now expects that the health services provider will post earnings per share of $4.31 for the year, down from their prior forecast of $4.51. The consensus estimate for Amedisys’ current full-year earnings is $4.43 per share. Leerink Partnrs also issued estimates for Amedisys’ Q4 2024 earnings at $0.96 EPS, Q1 2025 earnings at $1.20 EPS, Q2 2025 earnings at $1.50 EPS, Q3 2025 earnings at $1.17 EPS, Q4 2025 earnings at $1.04 EPS, FY2025 earnings at $4.90 EPS, Q1 2026 earnings at $1.24 EPS, Q2 2026 earnings at $1.54 EPS, Q3 2026 earnings at $1.20 EPS and Q4 2026 earnings at $1.08 EPS.

Amedisys Price Performance

Shares of NASDAQ:AMED opened at $92.41 on Friday. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys has a twelve month low of $82.15 and a twelve month high of $98.95. The company’s 50 day moving average is $89.37 and its 200 day moving average is $94.05. The company has a market cap of $3.03 billion, a PE ratio of 36.67, a price-to-earnings-growth ratio of 1.83 and a beta of 0.72.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $587.67 million for the quarter, compared to analyst estimates of $586.75 million. During the same period in the prior year, the firm posted $0.98 EPS. The business’s revenue was up 5.7% compared to the same quarter last year.

Hedge Funds Weigh In On Amedisys

Institutional investors and hedge funds have recently modified their holdings of the stock. Westchester Capital Management LLC lifted its position in shares of Amedisys by 9.5% during the 3rd quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider’s stock valued at $107,976,000 after buying an additional 97,476 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Amedisys by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after acquiring an additional 7,071 shares during the last quarter. Pacer Advisors Inc. raised its position in shares of Amedisys by 11,621.9% during the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock valued at $50,679,000 after buying an additional 553,435 shares during the period. Calamos Advisors LLC lifted its stake in shares of Amedisys by 22.7% in the 4th quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider’s stock valued at $44,255,000 after purchasing an additional 90,097 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Amedisys by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock valued at $33,400,000 after acquiring an additional 9,004 shares during the period. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.